

**LONGERICH, PROF. DR. THOMAS (M)**

(\*05.07.1974)



DIVISION HEAD

Institute of Pathology  
University Hospital  
Im Neuenheimer Feld 224  
69120 Heidelberg

Phone: 06221/56 39915

Email: [thomas.longerich@med.uni-heidelberg.de](mailto:thomas.longerich@med.uni-heidelberg.de)**ACADEMIC EDUCATION AND SCIENTIFIC DEGREES**

2011	Postdoctoral Lecture Qualification (Habilitation)
2003	MD-Thesis, Institute of Pathology, University of Cologne (magna cum laude; supervised by Prof. Dr. P. Schirmacher)
1995-2002	Study of Medicine, University of Cologne

**PROFESSIONAL CAREER**

Since 2017	Professor of General Pathology, Institute of Pathology, University of Heidelberg
2016-2017	Executive Senior Physician, Deputy Head, Institute of Pathology, RWTH Aachen
2015-2017	Head NGS Diagnostics, Institute of Pathology and Deputy Head, Center for NGS Diagnostics, University Hospital RWTH Aachen
2014-2017	Professor of Oncological Pathology, Institute of Pathology, RWTH Aachen
2012-2014	Consultant Pathologist, Institute of Pathology, University of Heidelberg
2010-2012	Consultant Pathologist for Hepatopathology, Institute of Pathology, University of Heidelberg
2009	Board Certification in Pathology
Since 2007	Research group leader

**AWARDS AND APPOINTMENTS**

2011	Poster award, 27 <sup>th</sup> Annual Meeting of the German Association for the Study of Liver disease (GASL), Regensburg; "Metabolism, Transport, Tumors"
2013	Member of the Laennec Liver Pathology Society
2014	Virchow Price, German Society of Pathology
2014	Distinguished Clinical Study 2014 "Efficacy and Non-Target Effects of TACE in Bridging of HCC Patients to Liver Transplantation - a Histopathological Study"; Journal of Vascular and Interventional Radiology.
2014	Professor of Oncological Pathology, Institute of Pathology, University Hospital RWTH Aachen (head: Prof. Ruth Knüchel-Clarke)
Since 2015	Deputy Coordinator of the Working Group Molecular High Throughput Diagnostic, German Society for Digestive and Metabolic Diseases

## SELECTED PUBLICATIONS

1. Mueller C, Waldburger N, Stampfl U, Kauczor HU, Schirmacher P, Sommer CM, **Longerich T** (2017) Non-invasive diagnosis of hepatocellular carcinoma revisited. *Gut*. 2017 Sep 12. pii: gutjnl-2017-314981. doi: 10.1136/gutjnl-2017-314981
2. Yuan D, Huang S, Berger E, Liu L, Gross N, Heinzmann F, Ringelhan M, Connor TO, Stadler M, Meister M, Weber J, Ollinger R, Simonavicius N, Reisinger F, Hartmann D, Meyer R, Reich M, Seehawer M, Leone V, Hochst B, Wohlleber D, Jors S, Prinz M, Spalding D, Protzer U, Luedde T, Terracciano L, Matter M, **Longerich T**, Knolle P, Ried T, Keitel V, Geisler F, Unger K, Cinnamon E, Pikarsky E, Huser N, Davis RJ, Tschaharganeh DF, Rad R, Weber A, Zender L, Haller D, Heikenwalder M (2017) Kupffer Cell-Derived Tnf Triggers Cholangiocellular Tumorigenesis through JNK due to Chronic Mitochondrial Dysfunction and ROS. *Cancer Cell* 31:771-789 e776.
3. Mueller S, Nahon P, Rausch V, Peccerella T, Silva I, Yagmur E, Straub BK, Lackner C, Seitz HK, Rufat P, Sutton A, Bantel H, **Longerich T** (2017) Caspase-cleaved keratin-18 fragments increase during alcohol withdrawal and predict liver-related death in patients with alcoholic liver disease. *Hepatology* 66:96-107.
4. Schneider AT, Gautheron J, Feoktistova M, Roderburg C, Loosen SH, Roy S, Benz F, Schemmer P, Buchler MW, Nachbur U, Neumann UP, Tolba R, Luedde M, Zucman-Rossi J, Panayotova-Dimitrova D, Leverkus M, Preisinger C, Tacke F, Trautwein C, **Longerich T**, Vucur M, Luedde T (2017) RIPK1 Suppresses a TRAF2-Dependent Pathway to Liver Cancer. *Cancer Cell* 31:94-109.
5. Endig J, Buitrago-Molina LE, Marhenke S, Reisinger F, Saborowski A, Schutt J, Limbourg F, Konecke C, Schreder A, Michael A, Misslitz AC, Healy ME, Geffers R, Clavel T, Haller D, Unger K, Finegold M, Weber A, Manns MP, **Longerich T**, Heikenwalder M, Vogel A (2016) Dual Role of the Adaptive Immune System in Liver Injury and Hepatocellular Carcinoma Development. *Cancer Cell* 30:308-323.
6. Elgohary N, Pellegrino R, Neumann O, Elzawahry HM, Saber MM, Zeeneldin AA, Geffers R, Ehemann V, Schemmer P, Schirmacher P, **Longerich T** (2015) Protumorigenic role of Timeless in hepatocellular carcinoma. *Int J Oncol* 46:597-606.
7. Rudalska R, Dauch D, **Longerich T**, McJunkin K, Wuestefeld T, Kang TW, Hohmeyer A, Pesic M, Leibold J, von Thun A, Schirmacher P, Zuber J, Weiss KH, Powers S, Malek NP, Eilers M, Sipos B, Lowe SW, Geffers R, Laufer S, Zender L (2014) In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. *Nat Med* 20:1138-1146.
8. Tschaharganeh DF, Xue W, Calvisi DF, Evert M, Michurina TV, Dow LE, Banito A, Katz SF, Kastenhuber ER, Weissmueller S, Huang CH, Lechel A, Andersen JB, Capper D, Zender L, **Longerich T**, Enikolopov G, Lowe SW (2014) p53-dependent Nestin regulation links tumor suppression to cellular plasticity in liver cancer. *Cell* 158:579-592.
9. Pellegrino R, Calvisi DF, Neumann O, Kolluru V, Wesely J, Chen X, Wang C, Wuestefeld T, Ladu S, Elgohary N, Bermejo JL, Radlwimmer B, Zornig M, Zender L, Dombrowski F, Evert M, Schirmacher P, **Longerich T** (2014) EEF1A2 inactivates p53 by way of PI3K/AKT/mTOR-dependent stabilization of MDM4 in hepatocellular carcinoma. *Hepatology* 59:1886-1899.
10. Neumann O, Kesselmeier M, Geffers R, Pellegrino R, Radlwimmer B, Hoffmann K, Ehemann V, Schemmer P, Schirmacher P, Bermejo JL, **Longerich T** (2012) Methyloome analysis and integrative profiling of human HCCs identify novel protumorigenic factors. *Hepatology* 56:1817-1827.